Directors' dealing & warrant extension

RNS Number : 4353Y

Yourgene Health PLC

09 May 2019

 

Yourgene Health plc

("Yourgene," the "Company")

Directors' dealing and warrant extension

Manchester, UK - 9 May 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it was notified yesterday by Barry Hextall and Hayden Jeffreys, both directors of the Company, that they respectively purchased 89,551 and 222,348 ordinary shares of 0.10p each in the Company yesterday at an average price of 11.2 pence per ordinary share. The table below details each directors' shareholdings:

Director	Shareholding prior to purchase  of shares	Number of ordinary shares purchased	Shareholding following purchase of shares	Ordinary shares held as percentage of issued voting share capital
Barry Hextall	432,518	89,551	522,069	0.09%
Hayden Jeffreys	0	222,348	222,348	0.04%

Extension of warrant

Furthermore, the Company announces that it has agreed to extend the exercise period by a year of a warrant granted over 1,411,227 ordinary shares that was scheduled to expire on 13 June 2019.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:
Yourgene Health plc Lyn Rees, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Head of Marketing [e-mail]	Tel: [phone]
Cairn Financial Advisers LLP (NOMAD) Liam Murray / James Caithie	Tel: [phone]
Stifel Nicolaus Europe Limited (Broker) Nicholas Moore / Matthew Balwat / Ben Maddison	Tel: [phone]
Vigo Communications Ben Simons / Fiona Henson / Antonia Pollock [e-mail]	Tel: [phone]

About Yourgene Health 

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions.

Yourgene Health's first commercialised products are NIPT for Down's Syndrome and other genetic disorders, targeting a share of an emerging billion-dollar global market.

Prenatal screening is an established clinical practice, but accuracy challenges with traditional methods are driving the need for NIPT and other DNA-based reproductive health testing solutions. Our commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Through our technical expertise and partnerships, Yourgene Health is aiming to extend its genetic testing offering into complementary areas of reproductive health and oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	(i)            Barry Hextall (ii)           Hayden Jeffreys
2	Reason for notification
a.	Position/Status	(i)            Chief Financial Officer (ii)           Chief Operating Officer
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Yourgene Health plc
b.	LEI	213800UUIT8BZE7QEH33
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 0.10p each ISIN: GB00BN31ZD89
b.	Nature of the transaction	Purchase of ordinary shares
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			(i)            11.5p (ii)           11.5p	(i)            89,551 (ii)           222,348
d.	Aggregated information - Aggregated Volume - Price	311,899 11.5p
e.	Date of the transaction	8 May 2019
f.	Place of the transaction	London Stock Exchange

 

END

 

 

DSHKMGGKVRGGLZM